Evidence map›Paper›PMID 39550386›Full record

ArticleNature communications2024

GPRC5A promotes lung colonization of esophageal squamous cell carcinoma.

Hongyu Zhou, Licheng Tan, Baifeng Zhang, Dora Lai Wan Kwong, Ching Ngar Wong, Yu Zhang, Beibei Ru, Yingchen Lyu, Kin To Hugo Siu, Jie Luo and 9 more

Abstract read
In one paragraph

Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Multi-omics characterization of a GPRC5AJournal of translational medicine · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Targeting ubiquitination in disease and therapy.Signal transduction and targeted therapy · 2025
    Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Hongyu Zhou *Department of Clinical Oncology, Centre for Cancer Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
Licheng Tan *Department of Clinical Oncology, Centre for Cancer Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
Baifeng Zhang *Department of Clinical Oncology, Centre for Cancer Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.ORCID 0000-0003-1966-2285
Dora Lai Wan KwongDepartment of Clinical Oncology, Centre for Cancer Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
Ching Ngar WongDepartment of Clinical Oncology, Centre for Cancer Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.ORCID 0000-0002-5034-7067
Yu ZhangDepartment of Pediatric Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China.
Beibei RuCancer Data Science Lab, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.ORCID 0000-0003-3897-7733
Yingchen LyuDepartment of Clinical Oncology, Centre for Cancer Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
Kin To Hugo SiuDepartment of Clinical Oncology, Centre for Cancer Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
Jie LuoDepartment of Clinical Oncology, Centre for Cancer Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
Yuma YangDepartment of Clinical Oncology, Centre for Cancer Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
Qin LiuDepartment of Clinical Oncology, Centre for Cancer Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
Yixin ChenDepartment of Liver Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Weiguang ZhangDepartment of Thoracic Surgery, Fujian Medical University Union Hospital, Fuzhou, China.
Chaohui HeDepartment of Cardiovascular Surgery, Songshan Lake Central Hospital of Dongguan City, Dongguan, China.
Peng JiangCancer Data Science Lab, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.ORCID 0000-0002-7828-5486
Yanru QinDepartment of Clinical Oncology, the First Affiliated Hospital, Zhengzhou University, Zhengzhou, China.
Beilei LiuDepartment of Clinical Oncology, Centre for Cancer Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China. bella007@connect.hku.hk.ORCID 0000-0002-0623-9093
Xin-Yuan GuanDepartment of Clinical Oncology, Centre for Cancer Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China. xyguan@hku.hk.ORCID 0000-0002-4485-6017

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Emerging evidence suggests that cancer cells may disseminate early, prior to the formation of traditional macro-metastases. However, the mechanisms underlying the seeding and transition of early disseminated cancer cells (DCCs) into metastatic tumors remain poorly understood. Through single-cell RNA sequencing, we show that early lung DCCs from esophageal squamous cell carcinoma (ESCC) exhibit a trophoblast-like 'tumor implantation' phenotype, which enhances their dissemination and supports metastatic growth. Notably, ESCC cells overexpressing GPRC5A demonstrate improved implantation and persistence, resulting in macro-metastases in the lungs. Clinically, elevated GPRC5A level is associated with poorer outcomes in a cohort of 148 ESCC patients. Mechanistically, GPRC5A is found to potentially interact with WWP1, facilitating the polyubiquitination and degradation of LATS1, thereby activating YAP1 signaling pathways essential for metastasis. Importantly, targeting YAP1 axis with CA3 or TED-347 significantly diminishes early implantation and macro-metastases. Thus, the GPRC5A/WWP1/LATS1/YAP1 pathway represents a crucial target for therapeutic intervention in ESCC lung metastases.

Indexed as

Esophageal NeoplasmsEsophageal Squamous Cell CarcinomaLung NeoplasmsProtein Serine-Threonine KinasesReceptors, G-Protein-CoupledUbiquitin-Protein LigasesYAP-Signaling ProteinsAdaptor Proteins, Signal TransducingAnimalsCell Line, TumorFemaleGene Expression Regulation, NeoplasticHumansMaleMiceMice, NudeAdaptor Proteins, Signal TransducingGPRC5A protein, humanLATS1 protein, humanProtein Serine-Threonine KinasesReceptors, G-Protein-CoupledTranscription FactorsUbiquitin-Protein LigasesYAP1 protein, humanYAP-Signaling Proteins

Identifiers

PMID39550386
PMCPMC11569164

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.